Information  X 
Enter a valid email address

Creo Medical Group (CREO)

  Print      Mail a friend

Monday 17 December, 2018

Creo Medical Group

Exercise of Options

RNS Number : 7363K
Creo Medical Group PLC
17 December 2018
 

Creo Medical Group plc

("Creo" or the "Company")

 

Exercise of Options

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, confirms that it has issued, conditional on admission, 172,440 new ordinary shares of £0.001 each in the capital of the Company (the "New Shares"), pursuant to an exercise of share options by an employee of the Company.

 

Application has been made to the London Stock Exchange for admission of the New Shares to trading on AIM and dealings are expected to commence on 21 December 2018 ("Admission").

 

Following Admission, Creo will have a total of 120,495,385 ordinary shares of £0.001 each in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in Creo.

 

 

Creo Medical Group plc

 

Richard Rees (CFO)

+44 (0)129 160 6005

 

 

Cenkos Securities

+44 (0)20 7397 8900

Stephen Keys/Mark Connelly (NOMAD)

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus

Mob: +44 (0)7980 541 893

Helen Cresswell

Mob: +44 (0)7841 917 679

 



 

About Creo Medical

 

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy.  The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy.  Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation.  This technology provides physicians with flexible, accurate and controlled surgical solutions.

 

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs.  The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures.  The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

 

For more information about Creo Medical please see our website, www.creomedical.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IOEGGGCPPUPRGQM

a d v e r t i s e m e n t